文章：

评估经动脉博来霉素-碘油栓塞术治疗巨大肝血管瘤疗效的预测因素

Evaluation of Predictive Factors for Transarterial Bleomycin–Lipiodol Embolization Success in Treating Giant Hepatic Hemangiomas

原文发布日期：26 December 2024

DOI: 10.3390/cancers17010042

类型: Article

开放获取: 是

英文摘要：

Introduction:Giant hepatic hemangiomas are challenging to manage, requiring effective therapeutic approaches. Transarterial bleomycin–lipiodol embolization (TACE) has shown promise as a treatment option, yet predictive factors for its success are not well defined. This study aimed to assess the efficacy of TACE for giant hepatic hemangiomas and identify factors influencing treatment outcomes.Methods:A retrospective analysis of 31 adult patients who underwent TACE with bleomycin and lipiodol between December 2014 and October 2022 was conducted. Clinical parameters including age, sex, hemangioma location, lesion size, bleomycin dose, number of TACE sessions, and follow-up duration were evaluated. The primary outcome was hemangioma volume reduction, with statistical analyses identifying factors associated with significant lesion regression.Results:Higher bleomycin doses and longer intervals from procedure to follow-up were positively correlated with hemangioma volume reduction, while variables such as patient sex and lesion location showed no statistically significant impact on clinical success. The findings suggest that increased bleomycin dosage and extended follow-up periods may enhance treatment efficacy.Conclusions:The study identifies bleomycin dose and follow-up duration as predictive factors for TACE success in treating giant hepatic hemangiomas, underscoring their role in optimizing therapeutic strategies. These insights contribute to improved treatment personalization for patients with giant hepatic hemangiomas and highlight the need for further prospective studies to validate and expand upon these findings.

摘要翻译： 

引言：巨大肝血管瘤的治疗具有挑战性，需要有效的治疗方法。经动脉博来霉素-碘油栓塞术（TACE）作为一种治疗选择已显示出潜力，但其疗效的预测因素尚未明确。本研究旨在评估TACE治疗巨大肝血管瘤的疗效，并确定影响治疗结果的因素。 方法：对2014年12月至2022年10月期间接受博来霉素和碘油TACE治疗的31例成年患者进行回顾性分析。评估的临床参数包括年龄、性别、血管瘤位置、病灶大小、博来霉素剂量、TACE治疗次数和随访时间。主要结局指标为血管瘤体积缩小，通过统计分析确定与病灶显著消退相关的因素。 结果：较高的博来霉素剂量以及从手术到随访的较长间隔时间与血管瘤体积缩小呈正相关，而患者性别和病灶位置等变量对临床成功率无统计学显著影响。研究结果表明，增加博来霉素剂量和延长随访时间可能提高治疗效果。 结论：本研究确定博来霉素剂量和随访时间是TACE治疗巨大肝血管瘤成功的预测因素，强调了它们在优化治疗策略中的作用。这些发现有助于改善巨大肝血管瘤患者的个体化治疗，并凸显了需要进一步开展前瞻性研究以验证和拓展这些结果。

原文链接：

Evaluation of Predictive Factors for Transarterial Bleomycin–Lipiodol Embolization Success in Treating Giant Hepatic Hemangiomas